Plasma Neurofilament Light Chain: A Potential Biomarker for Neurological Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

autonomic nervous system cognition myalgic encephalomyelitis/chronic fatigue syndrome neurofilament light chain

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
11 Jul 2024
Historique:
received: 30 05 2024
revised: 01 07 2024
accepted: 05 07 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 27 7 2024
Statut: epublish

Résumé

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disorder characterized by heterogeneous symptoms, which lack specific biomarkers for its diagnosis. This study aimed to investigate plasma neurofilament light chain (NfL) levels as a potential biomarker for ME/CFS and explore associations with cognitive, autonomic, and neuropathic symptoms. Here, 67 ME/CFS patients and 43 healthy controls (HCs) underwent comprehensive assessments, including neuropsychological evaluation, autonomic nervous system (ANS) testing, and plasma NfL level analysis. ME/CFS patients exhibited significantly higher plasma NfL levels compared to HC (F = 4.30,

Identifiants

pubmed: 39062112
pii: biomedicines12071539
doi: 10.3390/biomedicines12071539
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI20/01076
Organisme : Basque Government
ID : 2021111006
Organisme : Basque Government
ID : PRE_2023_2_0138
Organisme : Bioef - Fundación Vasca de Innovación e Investigación Sanitarias
ID : BIOS21/COV/006

Auteurs

Naiara Azcue (N)

Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.

Beatriz Tijero-Merino (B)

Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Department of Neurology, Cruces University Hospital-OSAKIDETZA, 48903 Barakaldo, Spain.
CIBERNED-CIBER, Institute Carlos III, 28029 Madrid, Spain.

Marian Acera (M)

Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.

Raquel Pérez-Garay (R)

Clinical Analysis Service, Cruces University Hospital, 48903 Barakaldo, Spain.

Tamara Fernández-Valle (T)

Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Department of Neurology, Cruces University Hospital-OSAKIDETZA, 48903 Barakaldo, Spain.

Naia Ayo-Mentxakatorre (N)

Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.

Marta Ruiz-López (M)

Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Department of Neurology, Cruces University Hospital-OSAKIDETZA, 48903 Barakaldo, Spain.

Jose Vicente Lafuente (JV)

Department of Neurosciences, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.

Juan Carlos Gómez Esteban (JC)

Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
Department of Neurology, Cruces University Hospital-OSAKIDETZA, 48903 Barakaldo, Spain.
CIBERNED-CIBER, Institute Carlos III, 28029 Madrid, Spain.
Department of Neurosciences, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.

Rocio Del Pino (R)

Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.

Classifications MeSH